申请人:Xention Limited
公开号:US08193215B2
公开(公告)日:2012-06-05
The invention provides compounds of the formula:
wherein
R1 is aryl, heteroaryl, cycloalkyl or alkyl;
R2 is H, alkyl, nitro, CO2R7, CONR5R6 or halo;
R3 and R4 are H, NR5R6, NC(O)R7, halo, trifluromethyl, alkyl, CONR5R6, CO2R7, nitrile or alkoxy;
R5 and R6 may be the same or different and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R5 and R6 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S;
R7 is H or alkyl;
A is H, halo, or a group of formula X-L-Y;
X is O, S or NR8;
R8 is H or alkyl;
L is (CH2)n, where n is 0, 1, 2, 3 or 4; and
Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl;
the products of mono- and di-oxidation of sulphur and/or mono-oxidation of nitrogen moieties in compounds of formula I;
or a pharmaceutically acceptable salt thereof.
These compounds find use as inhibitors of potassium ion channels and thus are useful in the treatment of various conditions including arrhythmia and type-2 diabetes mellitus.
该发明提供了以下式子的化合物:
其中,R1是芳基,杂环芳基,环烷基或烷基;
R2是H,烷基,硝基,CO2R7,CONR5R6或卤素;
R3和R4是H,NR5R6,NC(O)R7,卤素,三
氟甲基,烷基,CONR5R6,CO2R7,腈或烷氧基;
R5和R6可以相同也可以不同,可以是H,烷基,芳基,杂环芳基或环烷基;或者R5和R6可以共同形成一个饱和的、不饱和的或部分饱和的4至7成员环,其中该环可以选择性地包括一个或多个来自N、O或S的进一步杂原子;
R7是H或烷基;
A是H,卤素或式子X-L-Y的基团;
X是O,S或NR8;
R8是H或烷基;
L是(
CH2)n,其中n为0、1、2、3或4;
Y是芳基、杂环基、烷基、烯基或环烷基;
该式I化合物中
硫和/或氮基团的单氧化和双氧化产物;或其药学上可接受的盐。
这些化合物可用作
钾离子通道
抑制剂,因此对于治疗各种病症,包括心律失常和2型糖尿病非常有用。